Bladder Carcinoma — Trials

Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 141
Recruiting: 74
Ph III recruiting: 14
Growth YoY: +6.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 48.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 51–72 of 72 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04848519	Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	active not recruiting	Phase 2	6	Emory UniversityOTHER	1	Feb 19, 2026	clinicaltrials
NCT06470282	Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer	recruiting	Phase 1 / Phase 2	47	University of California, San FranciscoOTHER	1	Feb 18, 2026	clinicaltrials